Start free in MyPlan Read the GLP-1 nutrition guide Most trackers count a ceiling
Retatrutide builds upon this concept by targeting GLP-1, GIP, and glucagon receptors simultaneously
Phase 3 clinical trials are ongoing, with regulatory submissions expected and potential approval in the 2026-2027 timeframe
Reading Published Dose Ranges Correctly Retatrutides Phase 3 TRIUMPH-1 trial, with topline results reported by Eli Lilly in May 2026, evaluated three target doses 4mg, 9mg, and 12mg weekly with all arms starting at 2mg and escalating in steps every four weeks (2mg 4mg 6mg 9mg 12mg, depending on target arm) rather than starting at the target dose directly
it remains under clinical investigation and is not currently available for prescription
Mazdutide takes a targeted dual-receptor approach, activating both GLP-1 and glucagon receptors simultaneously